Bavarian Nordic (OTCMKTS:BVNRY) and Actuate Therapeutics (NASDAQ:ACTU) Head to Head Comparison

Bavarian Nordic (OTCMKTS:BVNRY) and Actuate Therapeutics (NASDAQ:ACTU) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Bavarian Nordic and Actuate Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bavarian Nordic	0	0	0	0	0.00
Actuate Therapeutics	1	0	2	0	2.33

Actuate Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 830.85%. Given Actuate Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than Bavarian Nordic.

Profitability

This table compares Bavarian Nordic and Actuate Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bavarian Nordic	19.74%	9.37%	8.10%
Actuate Therapeutics	N/A	-430.93%	-180.86%

Earnings & Valuation

This table compares Bavarian Nordic and Actuate Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bavarian Nordic	$945.43 million	2.39	$208.23 million	$0.76	12.49
Actuate Therapeutics	N/A	N/A	-$22.23 million	($0.97)	-1.94

Bavarian Nordic has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Bavarian Nordic, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Bavarian Nordic has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Actuate Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Summary

Bavarian Nordic beats Actuate Therapeutics on 8 of the 11 factors compared between the two stocks.

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

About Actuate Therapeutics

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.